Industry veterans, Drs. Debasish Roychowdhury and John Lambert appointed to the SAB
Belgium, 20 October 2020 – atbtherapeutics, a pioneering biopharmaceutical company building an oncology pipeline using its antibody–toxin-bioengineered atbody format, announces that Debasish Roychowdhury MD, PhD and John Lambert PhD have been appointed as Scientific Advisors to bolster the development of its pipeline. Their experience and knowledge in the fields of antibody drug conjugates and oncology drug development, strengthens the Scientific Advisory Board and will be highly valuable as atbtherapeutics progresses its pipeline towards the clinic.
Dr Bertrand Magy, CEO at atbtherapeutics, commented: “The appointment of Dr. Debasish Roychowdhury and Dr. John Lambert as Scientific Advisors brings great validation to atbtherapeutics and will greatly strengthen its offering. Both individuals have impressive track records in the development of anti-cancer therapies; their clinical insights will be instrumental to help crystallize our focus as we progress our pipeline towards the clinic.”
Dr Debasish Roychowdhury is the co-founder and Chief Technology Officer of Partner Therapeutics and has served as the Chief Medical Officer at Seragon and Ra Pharmaceuticals, and as a consultant for other biotech companies and academic centers. Prior to Seragon, Debasish also served as Senior Vice President and Head of the Global Oncology Division at Sanofi and Vice President for Clinical Development at GlaxoSmithKline, and directed the Oncology global regulatory group at Eli Lilly and Company. Prior to his industry roles, he served as faculty member at the University of Cincinnati, Ohio, USA. Debasish is a member of the Board of Directors for ImCheck Therapeutics, T-knife Biotechnology, Monopteros Therapeutics, Lytix Biopharma AS and Fund+, serves in multiple scientific advisory boards and is on the faculty of the Department of Biological Engineering at MIT. Debasish trained at the All India Institute of Medical Sciences, India, and University of California, San Francisco, USA.
“ADCs are quickly becoming standard options in many cancers and atbtherapeutics can dramatically improve this area by its highly differentiated novel pipeline,” said Dr. Roychowdhury. He added “in addition to their atbody agents and multi-asset pipeline, their innovative plant-based manufacturing platform demonstrates great potential for future expansion and collaborations”.
Dr John Lambert is one of the leading experts in the field of ADC discovery and development. He joined ImmunoGen in 1987 and served as Chief Scientific Officer from 2008 until 2015, and was subsequently Distinguished Research Fellow at ImmunoGen until retirement in 2018. During John’s tenure in leadership roles, ImmunoGen invented the antibody-drug conjugate technology that resulted in Kadcyla® (Genentech/Roche) and mirvetuximab soravtansine (ImmunoGen), which is in pivotal trials for treating platinum-resistant ovarian cancer. Prior to this, John joined the Dana-Farber Cancer Institute at Harvard Medical School to work on ImmunoGen-funded programs to develop antibody-drug conjugates (ADCs) and immunotoxins as anti-cancer therapeutics. In 2016, Dr Lambert was elected Fellow of the American Institute for Medical and Biological Engineering. In 2018, he was appointed Honorary Professor of Queen’s University Belfast, UK. John graduated from Christ’s College, University of Cambridge, UK with a degree in Natural Sciences, and earned a PhD in Biochemistry from the University of Cambridge under the supervision of Professor Richard N. Perham. His postdoctoral training was at the University of California, Davis, (US), and the University of Glasgow, Scotland.
atbtherapeutics is a pioneering biopharmaceutical company building a pipeline of novel biologic agents for cancer using its antibody–toxin-bioengineered atbody format, manufactured by its disruptive atbiofarm technology.
atbtherapeutics' proprietary and versatile plant-based atbiofarm technology enables the production of a targeted monoclonal antibody therapy of significantly improved potency and efficacy – the atbody.
atbodies are fusion proteins recombinantly manufactured in a single-step process, composed of a full-length antibody, a peptide linker and a toxic peptide payload. The unique composition of the atbody format, avoiding chemical linker issues, generates increased potency, stability and superior targeted exposure, potentially reducing the therapeutic dose needed without compromising efficacy. The resulting novel mechanism of action also means that atbody therapeutics has the potential to evade major mechanisms of cancer cell resistance, providing a promising therapeutic solution for hard-to-treat and refractory cancer.
atbtherapeutics is a private company founded in 2018 with seed financing from Financière Spin Off Luxembourgeoise, the Fournier-Majoie Foundation and Noshaq, and has raised a total of EUR 5.1 million in equity and subsidies from the Region Wallonne with additional investment from historical investors and Luxembourg Development.
atbtherapeutics’ Management Team is supported by a strong, diverse and international network of experienced board members and advisors.
atbtherapeutics is headquartered in Belgium.
Find out more here: www.atbtherapeutics.com
Connect with us on: Twitter and LinkedIn
For more information please contact: firstname.lastname@example.org